BCR and chronic myelogenous leukemia, BCR-ABL1 positive: Given the novel generation of ABL inhibitors with improved potency have been developed, a further direction would be the combination of KPT-330 and newer ABL inhibitors, which could abrogate the catalytic activity of all or most BCR-ABL mutants found in IM-resistant CML.